Pricing Log in Create free account
Friday 6 November 2026 Export COLL’s income statement to Excel — free account

Collegium Pharmaceutical, Inc.

COLL Healthcare Drug Manufacturers Specialty & Generic

Collegium Pharmaceutical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $780.6 million, up 23.6% from fiscal 2024.

Revenue
+3.33%
EPS
−31.0%
Free cash flow
+10.2%
Total debt
+33.8%

Quarter to September 2026, against a year earlier

25.07 1.40 +5.91%
Market cap
$819.1M
P/E
20.5×
Fwd P/E
21.3×
Dividend yield
—
F-score
7/9
Altman Z
1.58
Beneish M
−3.32
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 4.38
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 2 — — 3 — 4 — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 819.10
Revenue ttm 815.19
Net income ttm 38.17
Free cash flow ttm 336.29
Net debt Q 1,081.50
Valuation
P/E 20.55
Forward P/E 21.30
Price / sales 0.98
Forward P/S Powerpack
Price / FCF 0.00
Price / book 2.68
Financial health
Current ratio Q 1.01
Debt / equity Q 3.65 (above 2: weak)
Interest coverage Q 1.31
Growth
Revenue growth Q +3.33% (above 0%: growing)
Operating income growth Q −53.74% (below 0%: shrinking)
EPS, this year +0.32%
EPS, next year A −5.63% (below 0%: weak)
Revenue, next year A +6.73%
EPS, past 5 yrs +17.88% (at or above 15%: strong)
EPS, next 5 yrs A +0.78%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.1×, against a ten-year median of 2.6×; over the ten years it ranged from 0.8× in 2019 to 34.9× in 2017.
P/E against its own 10 years 62.40%
10-year low 10-year high
P/S against its own 10 years 1.96%
10-year low 10-year high
P/B against its own 10 years 7.77%
10-year low 10-year high
EV/Sales against its own 10 years 19.65%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 311 188 407 —
Receivables 180 229 211 311
Inventory 32 36 41 88
Other — — — —
538 482 691 612
2023 2024 2025 Q'26
Payables 9 4 11 10
ST’ Debt 183 65 29 61
Other — 29 18 —
458 510 440 603

Compound Annual Growth %

10y 5y 3y
Sales — 20.28% 18.94%
Cash Flow 0.00% 28.51% 38.40%
Earnings 0.00% 18.64% 0.00%
Book Value 13.49% 10.15% 15.69%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 1.68 Actual 1.92

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 1.88 2.25 Beat by 0.37
Q4 FY25 2.19 2.04 Miss by 0.15
Q1 FY26 1.42 1.76 Beat by 0.34
Q2 FY26 1.68 1.92 Beat by 0.24
Q3 FY26 1.77 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 0.40 (0.46) 0.60 — —
’25 0.07 0.34 0.84 0.46 1.73
’24 0.71 0.52 0.27 0.36 1.86
’23 (0.51) 0.34 0.53 0.82 1.29
’22 (0.39) (0.15) 0.01 (0.21) (0.74)
’21 0.41 1.79 0.22 (0.73) 1.86
’20 0.01 0.23 0.32 0.20 0.76
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 194 200 216 — —
’25 178 188 209 205 781
’24 145 145 159 182 631
’23 145 136 137 150 567
’22 84 124 127 130 464
’21 88 83 79 27 277
’20 77 78 79 76 310
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 57 71 87 — —
’25 55 72 78 123 329
’24 62 67 (9) 85 205
’23 28 100 74 73 275
’22 (25) 40 43 66 124
’21 21 30 17 36 104
’20 (7) 44 34 23 94
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 57 71 86 — —
’25 55 72 78 122 328
’24 61 67 (9) 84 203
’23 27 100 74 73 274
’22 (25) 40 43 65 123
’21 20 29 17 36 102
’20 (374) 42 32 21 (280)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 2 28 280 297 310 277 464 567 631 781 815 +97.5% 833 845 849 +2.8%
Gross margin, % 87.55 90.89 40.92 34.73 58.01 54.40 45.15 57.55 59.76 59.35 59.05 (28.2) pt
EBT (94) (75) (39) (23) 28 (3) (29) 76 99 93 42 n/m
EBT margin, % (5,504.15) (262.91) (13.95) (7.66) 8.90 (1.22) (6.22) 13.36 15.61 11.87 5.17 +5,516.0 pt
Net income (94) (75) (39) (23) 27 72 (25) 48 69 63 38 n/m
Per share, $
Per share, $ Revenue 0.07 0.94 8.51 8.87 9.01 7.92 13.71 16.80 19.57 24.62 25.69 +91.7%
Earnings (3.88) (2.47) (1.19) (0.68) 0.78 2.05 (0.74) 1.43 2.14 1.98 1.22 n/m
Cash flow (3.09) (2.21) 5.14 0.83 2.73 2.96 3.67 8.14 6.35 10.39 10.65 n/m
Capex (0.02) (0.03) (0.74) (0.19) (10.86) (0.06) (0.05) (0.01) (0.05) (0.05) (0.05) +12.1%
Free cash flow (3.11) (2.25) 4.40 0.64 (8.13) 2.91 3.62 8.13 6.30 10.33 10.60 n/m
Book value 5.56 3.44 2.78 2.61 5.41 5.81 5.76 5.79 7.09 9.51 9.34 +6.2%
Shares, m 24 30 33 33 34 35 34 34 32 32 32 +3.0%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 26.01 9.29 0.00 21.24 13.39 23.15 20.55 9.3
P/S 0.00 19.87 2.02 2.32 2.22 2.36 1.72 1.86 1.46 1.88 0.98 3.6
P/B 2.82 5.44 6.18 7.87 3.70 3.22 4.09 5.39 4.04 4.87 2.68 4.8
EV/Sales 0.00 15.77 1.54 1.79 2.49 2.59 2.86 2.49 2.52 2.40 2.12 3.4
EV/FCF (3.06) (6.60) 3.02 (16,561.38) (2.76) (2.69) (5.39) (15.01) (9.64) (46.03) (54.09) (1,665.0)
Cash, $m
Cash, $m Operating cash flow (75) (67) 169 28 94 104 124 275 205 329 338 n/m
Capex 0 (1) (24) (6) (374) (2) (2) 0 (2) (2) (2) +15.5%
Free cash flow (76) (68) 145 21 (280) 102 123 274 203 328 336 n/m
Balance, $m
Balance, $m Working capital 133 102 48 54 38 36 (14) 80 (27) 251 9 +7.3%
Net debt (149) (117) (135) (159) 83 64 527 357 665 403 1,082 n/m
Shareholders’ equity 135 104 92 87 186 203 195 195 229 302 296 +9.4%
Returns, %
Returns, % ROA (72.52) (50.32) (18.33) (7.61) 5.63 10.71 (2.68) 4.16 4.93 3.79 2.06 +76.3 pt
ROIC 0.00 0.00 0.00 0.00 13.06 4.13 2.88 18.90 11.88 15.94 5.63 +15.9 pt
ROE (85.62) (62.65) (39.99) (25.39) 19.57 36.77 (12.57) 24.68 32.62 23.70 13.36 +109.3 pt
People
People Employees 234 250 266 255 234 152 207 197 357 423 — +6.8%
Revenue/emp, $m 0.01 0.11 1.05 1.16 1.32 1.82 2.24 2.88 1.77 1.85 — +84.9%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Collegium Pharmaceutical, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CRON Cronos Group Inc. $1.4B 21.9× 19.5× +74.61% (above 0%: growing) −42.86% (below 0%: shrinking) +179.64% (above 0%: growing) 50.88% 14.23% Compare
AMPH Amphastar Pharmaceuticals, Inc. $1.2B 12.3× 12.8× +8.22% (above 0%: growing) +134.21% (above 0%: growing) −29.38% (below 0%: shrinking) 47.99% 24.46% Compare
HROW Harrow, Inc. $976.2M — (loss-making) — (loss-making) +10.85% (above 0%: growing) n/m −838.78% (below 0%: shrinking) 71.27% (15.58%) Compare
COLL Collegium Pharmaceutical, Inc. $819.1M 20.5× 21.3× +3.33% (above 0%: growing) −31.00% (below 0%: shrinking) +10.24% (above 0%: growing) 57.97% 13.28%
IRWD Ironwood Pharmaceuticals, Inc. $665.9M 4.3× 2.9× +9.00% (above 0%: growing) +44.00% (above 0%: growing) +41.66% (above 0%: growing) 100.00% 70.00% Compare
EVO Evotec AG $630.4M — (loss-making) — (loss-making) −12.98% (below 0%: shrinking) n/m −9,727.20% (below 0%: shrinking) (1.00%) (77.50%) Compare
TKNO Alpha Teknova, Inc. $486.2M — (loss-making) — (loss-making) +21.52% (above 0%: growing) n/m +40.94% (above 0%: growing) 37.99% (25.24%) Compare
AQST Aquestive Therapeutics, Inc. $460.0M — (loss-making) — (loss-making) −40.99% (below 0%: shrinking) n/m +40.78% (above 0%: growing) 52.28% (191.46%) Compare
EOLS Evolus, Inc. $448.8M — (loss-making) — (loss-making) +13.03% (above 0%: growing) n/m +77.73% (above 0%: growing) 65.02% (10.81%) Compare
Median of peers $648.2M 12.3× 12.8× +9.93% +44.00% +40.86% 51.58% (13.19%)

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 7 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 1.72m 7.86m 224.98
2023 9.14m 15.00m 149.56
2022 6.92m 10.49m 112.73
2021 7.31m 5.08m 90.77

Ownership

Directors and executive officers, together 1.85%
BlackRock, Inc. 15.40%
The Vanguard Group, Inc. 7.14%
Eventide Asset Management, LLC 5.79%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Collegium Pharmaceutical, Inc. (COLL) Latest News

5 Nov

Impact 3 · · Moby
Impact 3 · · The Motley Fool transcript
Impact 3 · · MarketBeat transcript
Impact 3 · · StockStory
Impact 3 · · GlobeNewswire

29 Oct

Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

26 Oct

Impact 3 · · StockStory

22 Oct

Impact 3 · · GlobeNewswire

21 Oct

Impact 3 · · GlobeNewswire

19 Oct

Impact 4 · · Zacks

16 Oct

Impact 3 · · Zacks

9 Oct

Impact 3 · · MT Newswires

6 Oct

Impact 3 · · GlobeNewswire

22 Sep

Impact 3 · · StockStory

15 Aug

Impact 3 ·

13 Aug

Impact 4 · · The Motley Fool transcript
Impact 3 ·

9 Aug

Impact 4 ·

6 Aug

Impact 4 · transcript
Impact 4 · · MarketBeat transcript
Impact 3 · · Moby transcript
Impact 3 ·
Impact 3 ·

19 Jul

Impact 3 ·

27 May

Impact 3 · · Insider Monkey

18 May

Impact 3 · · StockStory

14 May

Impact 4 ·

13 May

Impact 3 · · StockStory

12 May

Impact 4 · · GlobeNewswire
stockrow.com/COLL · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com